Novel therapeutic approaches to autosomal dominant polycystic kidney disease

Wells B. Lariviere, Maria Irazabal Mira, Vicente Torres

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the progressive growth of renal cysts that, over time, destroy the architecture of the renal parenchyma and typically lead to kidney failure by the sixth decade of life. ADPKD is common and represents a leading cause of renal failure worldwide. Currently, there are no Food and Drug Administration-approved treatments for the disease, and the existing standard of care is primarily supportive in nature. However, significant advances in the understanding of the molecular biology of the disease have inspired investigation into potential new therapies. Several drugs designed to slow or arrest the progression of ADPKD have shown promise in preclinical models and clinical trials, including vasopressin receptor antagonists and somatostatin analogs. This article examines the literature underlying the rationale for molecular therapies for ADPKD and reviews the existing clinical evidence for their indication for human patients with the disease.

Original languageEnglish (US)
Article number852
Pages (from-to)488-498
Number of pages11
JournalTranslational Research
Volume165
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Autosomal Dominant Polycystic Kidney
Renal Insufficiency
Kidney
United States Food and Drug Administration
Therapeutics
Standard of Care
Somatostatin
Cysts
Molecular Biology
Clinical Trials
Molecular biology
Growth
Pharmaceutical Preparations

Keywords

  • ADPKD
  • AMP-activated protein kinase
  • AMPK
  • autosomal dominant polycystic kidney disease
  • cAMP
  • CFTR
  • cyclic adenosine 3',5'-monophosphate
  • cystic fibrosis transmembrane conductance regulator
  • end-stage renal disease
  • ESRD
  • mammalian target of rapamycin
  • mTOR
  • PC1
  • PC2
  • polycystin-1
  • polycystin-2
  • V2R
  • vasopressin V2 receptor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Novel therapeutic approaches to autosomal dominant polycystic kidney disease. / Lariviere, Wells B.; Irazabal Mira, Maria; Torres, Vicente.

In: Translational Research, Vol. 165, No. 4, 852, 01.04.2015, p. 488-498.

Research output: Contribution to journalArticle

@article{939110bd1d9a4aeb9b309b497e0097fc,
title = "Novel therapeutic approaches to autosomal dominant polycystic kidney disease",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the progressive growth of renal cysts that, over time, destroy the architecture of the renal parenchyma and typically lead to kidney failure by the sixth decade of life. ADPKD is common and represents a leading cause of renal failure worldwide. Currently, there are no Food and Drug Administration-approved treatments for the disease, and the existing standard of care is primarily supportive in nature. However, significant advances in the understanding of the molecular biology of the disease have inspired investigation into potential new therapies. Several drugs designed to slow or arrest the progression of ADPKD have shown promise in preclinical models and clinical trials, including vasopressin receptor antagonists and somatostatin analogs. This article examines the literature underlying the rationale for molecular therapies for ADPKD and reviews the existing clinical evidence for their indication for human patients with the disease.",
keywords = "ADPKD, AMP-activated protein kinase, AMPK, autosomal dominant polycystic kidney disease, cAMP, CFTR, cyclic adenosine 3',5'-monophosphate, cystic fibrosis transmembrane conductance regulator, end-stage renal disease, ESRD, mammalian target of rapamycin, mTOR, PC1, PC2, polycystin-1, polycystin-2, V2R, vasopressin V2 receptor",
author = "Lariviere, {Wells B.} and {Irazabal Mira}, Maria and Vicente Torres",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.trsl.2014.11.003",
language = "English (US)",
volume = "165",
pages = "488--498",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Novel therapeutic approaches to autosomal dominant polycystic kidney disease

AU - Lariviere, Wells B.

AU - Irazabal Mira, Maria

AU - Torres, Vicente

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the progressive growth of renal cysts that, over time, destroy the architecture of the renal parenchyma and typically lead to kidney failure by the sixth decade of life. ADPKD is common and represents a leading cause of renal failure worldwide. Currently, there are no Food and Drug Administration-approved treatments for the disease, and the existing standard of care is primarily supportive in nature. However, significant advances in the understanding of the molecular biology of the disease have inspired investigation into potential new therapies. Several drugs designed to slow or arrest the progression of ADPKD have shown promise in preclinical models and clinical trials, including vasopressin receptor antagonists and somatostatin analogs. This article examines the literature underlying the rationale for molecular therapies for ADPKD and reviews the existing clinical evidence for their indication for human patients with the disease.

AB - Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the progressive growth of renal cysts that, over time, destroy the architecture of the renal parenchyma and typically lead to kidney failure by the sixth decade of life. ADPKD is common and represents a leading cause of renal failure worldwide. Currently, there are no Food and Drug Administration-approved treatments for the disease, and the existing standard of care is primarily supportive in nature. However, significant advances in the understanding of the molecular biology of the disease have inspired investigation into potential new therapies. Several drugs designed to slow or arrest the progression of ADPKD have shown promise in preclinical models and clinical trials, including vasopressin receptor antagonists and somatostatin analogs. This article examines the literature underlying the rationale for molecular therapies for ADPKD and reviews the existing clinical evidence for their indication for human patients with the disease.

KW - ADPKD

KW - AMP-activated protein kinase

KW - AMPK

KW - autosomal dominant polycystic kidney disease

KW - cAMP

KW - CFTR

KW - cyclic adenosine 3',5'-monophosphate

KW - cystic fibrosis transmembrane conductance regulator

KW - end-stage renal disease

KW - ESRD

KW - mammalian target of rapamycin

KW - mTOR

KW - PC1

KW - PC2

KW - polycystin-1

KW - polycystin-2

KW - V2R

KW - vasopressin V2 receptor

UR - http://www.scopus.com/inward/record.url?scp=84925110439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925110439&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2014.11.003

DO - 10.1016/j.trsl.2014.11.003

M3 - Article

VL - 165

SP - 488

EP - 498

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 4

M1 - 852

ER -